Immune Therapeutics Inc. Management Advises All Shareholders to Vote Their Proxy Card Today

    NEXT STORY
    BAHAMAS: PROJECT HOPE PROVIDES URGENTLY NEEDED MEDICAL CARE TO HURRICANE DORIAN SURVIVORS
    PREV STORY
    Helsinn demonstrates commitment to MF CTCL with multiple scientific sessions at the EORTC Cutaneous Lymphoma Meeting 2019
    Subscribe to PM360
    Print Subscription
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    Atara Biotherapeutics Announces Appointment of Utpal Koppikar as Chief Financial Officer

    SOUTH SAN FRANCISCO, Calif., June 07, 2018 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), ...

    author_avatar
    NASDAQ Market News

    G1 Therapeutics to Present Clinical Data on CDK4/6 Inhibitor Trilaciclib at the 2017 American Society of Clinical Oncology Annual Meeting

    RESEARCH TRIANGLE PARK, N.C., May 30, 2017 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (NASDAQ:GTHX), ...

    author_avatar
    NASDAQ Market News

    Mateon Therapeutics Announces Results from Second Interim Analysis of CA4P Phase 2/3 FOCUS Study in Platinum-resistant Ovarian Cancer

    Primary Endpoint - Early Progression Free Survival data favors CA4PCA4P continues to be safe ...

    author_avatar
    NASDAQ Market News